Longboard Pharmaceuticals, Inc. (LBPH)

Market Cap	2.33B
Revenue (ttm)	n/a
Net Income (ttm)	-76.34M
Shares Out	39.05M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	373,758
Open	59.78
Previous Close	59.75
Day's Range	59.71 - 59.82
52-Week Range	3.60 - 59.95
Beta	1.09
Analysts	Buy
Price Target	52.29 (-12.5%)
Earnings Date	Nov 7, 2024

About LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 12, 2021
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: LBPH
• Website: https://www.longboardpharma.com

Analyst Forecast

According to 8 analysts, the average rating for LBPH stock is "Buy." The 12-month stock price forecast is $52.29, which is a decrease of -12.50% from the latest price.

Price Target

$52.29

(-12.50% downside)

Analyst Consensus: Buy